INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie -- PCYC

The following statement is being issued by Levi & Korsinsky, LLP:

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF PHARMACYCLICS INC. PRIOR TO MARCH 4, 2015 AND CONTINUE TO HOLD SUCH SHARES.

YOU ARE HEREBY NOTIFIED that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Pharmacyclics Inc. (“Pharmacyclics”) (Nasdaq: PCYC). Click here to learn more about the action: http://zlk.9nl.com/pharmacyclics-pcyc. There is no cost or obligation to you.

The Board of Directors of Pharmacyclics agreed to sell the company to AbbVie (NYSE: ABBV). Under the terms of the transaction, Pharmacyclics shareholders will receive $261.25 per share in cash and stock. The investigation concerns whether the Board of Pharmacyclics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether AbbVie is underpaying for Pharmacyclics shares.

If you own Pharmacyclics common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/pharmacyclics-pcyc.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.